Pharnext has been testing PXT3003 (a fixed-dose combination of baclofen, naltrexone and sorbitol) in the pivotal PREMIER trial, which recruited a subgroup of patients with type 1 CMT, the most ...

Method. The article is based on literature searches in PubMed using the keyphrases «spasticity» and «spasticity AND spinal cord injury», and own clinical experience and research.

07.04.2021: Clinical review - Many medicines prescribed for older patients have an unintended anticholinergic effect in addition to the primary intended effect.